Eli Lilly's Phase 3 obesity programme for retatrutide (master protocol J1I-MC-GZBJ) remains in active follow-up with no NDA (New Drug Application) or MAA (Marketing Authorisation Application) filing recorded in 20242026 pipeline disclosures [1][2]
Emerging evidence indicates that lipid traits may have a role in DR as well, though work to understand this mechanism is still being conducted [79]
Effective programs pair GLP-1 therapy with lifestyle change, medication optimization and de-escalation, coaching, side-effect management and care escalation
Canadian Regulatory Context Research peptides occupy a regulatory grey area in Canada
GHK-Copper markedly improves skin's complexion, reduces appearance of wrinkles and helps restore a lifted and youthful look, especially when used in conjunction with other Skin Biology's products such as Two Timing Tightener (DMAE firming serum)
FDA approval requires an application with evidence on quality, safety, and effectiveness for a specific medical use